Court denies JHL motion to dismiss trade secret theft suit, bars development or sale of biosimilars that rely on information from Genentech documents; trial scheduled to begin in November 2020.
JHL Biotech Inc.'s development of biosimilars to Genentech Inc.'s Rituxan, Herceptin, Avastin, and Pulmozyme may be hampered by a court order barring the company's use of Genentech documents.
US District Judge William Alsup, of the Northern District of California, denied JHL's motion to dismiss Genentech's trade secrets theft...
Create an account to read this article
Already a subscriber?
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
Generic drug industry representatives applauded the FDA decision to bring back key staff in the Office of Generic Drugs that were laid off earlier this year.
The White House is directing the Health and Human Services Department to replenish stockpiles of active pharmaceutical ingredients for “especially critical” medicines.
